To reduce the risk of HIV infection today European Medicines Agency (EMA) announced it has adopted a positive opinion of a scientist on the dapivirine vaginal ring for use by cisgender women ages 18 and older. It will be an essential step for all those women sub-Saharan Africa towards options available in biomedical HIV prevention who are among those most affected by the HIV epidemic.

The National Institute of Allergy and Infectious Diseases (NIAID), thanks and applause everyone to led, curated and participated in the research of this positive opinion for women who are suffering from HIV.

This dapivirine ring made with flexible silicone and continuously releases the anti-HIV drug dapivirine in the vagina. The dapivirine users can use it in the long term around 1 month.

According to UNAIDS, more than 1.5 million  HIV  new cases worldwide held among ages 15 and older than that. Now, women have not been many options available to HIV prevention, also many women are not comfortable to talk about condom use with their sexual partners. Women need options for discreet HIV prevention tools that they can initiate, and the dapivirine ring is one such choice or tool.

This dapivirine ring has been two large clinical trials one of which was funded in part by NIAID, and the result will be that this ring in the east and southern Africa has reduced the risk of HIV infection approximately 30 per cent overall in cisgender women ages 18 to 45 years. But, NIAID hadn’t revealed yet that this ring provided no statistically significant protection in cisgender women who’s below the age of 25 years may be due to low product use.

These trials have been carried out by NIAID’s companions in analysis on the dapivirine ring: the NIH-funded Microbicide Trials Community (MTN) and the nonprofit Worldwide Partnership for Microbicides (IPM). The NIAID trial was additionally funded by the Eunice Kennedy Shriver Nationwide Institute on Youngster Well being and Human Growth (NICHD) and the Nationwide Institute on Mental Health (NIMH), each a part of NIH..”

The sponsor of the product is IPM who designed and developed it. Also, the WHO (World Health Organization) could now include the dapivirine ring in it’s HIV prevention recommendations and guidelines. As well as, after collaboration with WHO, IPM wants to approval for the ring from African national regulatory authorities. So, they fastly working on its manufacturing and provide it to countries where most woman faces a very high risk of HIV.

As the EMA has requested, IPM will organise extra analysis amongst cisgender women ages 18 to 25 years to raised perceive the ring’s efficacy and to gather extra knowledge on security and potential resistance to anti-HIV medication.

LEAVE A REPLY

Please enter your comment!
Please enter your name here